As populations age worldwide, chronic cor pulmonale and coronary artery disease frequently coexist in elderly patients, with each condition exacerbating the other’s pathophysiology, leading to more complex clinical presentations and greater therapeutic challenges. In this conceptual study, we propose an integrated clinical-observation framework for managing elderly patients who have both chronic cor pulmonale and coronary artery disease. Drawing on four key dimensions—pathophysiological characteristics, diagnostic and assessment indices, treatment-plan design, and efficacy-monitoring methods—we outline a systematic intervention strategy and evaluation model. By synthesizing existing literature, we identify the critical interaction targets between respiratory and cardiovascular systems and, guided by evidence-based principles, recommend a personalized combination of pharmacological therapies (including diuretics, β-blockers, and agents targeting pulmonary hypertension), non-pharmacological interventions (pulmonary rehabilitation, nutritional support), and, when appropriate, cardiac interventional or surgical procedures. Within this conceptual framework, we establish core efficacy metrics centered on exercise tolerance, hemodynamic parameters, and quality-of-life assessments to inform future clinical trials. Our findings suggest that a structured, multidisciplinary treatment approach may significantly improve cardiopulmonary function, reduce hospitalization rates, and enhance quality of life in elderly patients, while providing theoretical and practical guidance for clinical decision-making and guideline development.

Zhu Hezhong. Clinical Treatment Observation of Elderly Patients with Chronic Cor Pulmonale Combined with Coronary Artery Disease. International Journal of Frontiers in Medicine (2025), Vol. 7, Issue 3: 17-23. https://doi.org/10.25236/IJFM.2025.070302.

[1] Cacciatore, Stefano, et al. "Management of coronary artery disease in older adults: recent advances and gaps in evidence." Journal of clinical medicine 12.16 (2023): 5233.

[2] Aisanov, Zaurbek, and Nikolai Khaltaev. "Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients." Journal of thoracic disease 12.5 (2020): 2791.

[3] Xie, Xiangmei, et al. "[Retracted] Effects of Cardiopulmonary Rehabilitation Promotion Mode Intervention Combined with Oxygen Therapy on Cardiopulmonary Function and Blood Gas Analysis Indexes of COPD Patients with Cor Pulmonale." Journal of Healthcare Engineering 2022.1 (2022): 8495996.

[4] Kahnert, Kathrin, et al. "The diagnosis and treatment of COPD and its comorbidities." Deutsches Ärzteblatt International 120.25 (2023): 434.

[5] Jia, Enxia. "[Retracted] The Combination Clinical Value of Plasma Brain Natriuretic Peptide and Serum HbAlc in the Diagnosis of Chronic Pulmonary Heart Disease." Computational and Mathematical Methods in Medicine 2022.1 (2022): 6932179.

[6] Emelyanova, Nataliya, and Irina Komir. "Effect of drug-induced pathomorphosis on oral cavity organs and tissues in chronic obstructive pulmonary disease combined with coronary heart disease: A clinical case." Biomedical Research and Therapy 8.1 (2021): 4197-4202.

[7] Ramalho, Sergio HR, and Amil M. Shah. "Lung function and cardiovascular disease: a link." Trends in cardiovascular medicine 31.2 (2021): 93-98.

[8] Shen, Zinuo, et al. "The efficacy of sodium ferulate combination therapy in coronary heart disease: a systematic review and meta-analysis." Phytomedicine 115 (2023): 154829.

[9] Gao, Yang, et al. "The impact of sacrubitril/valsartan on clinical treatment and hs-cTnT and NT-ProBNP serum levels and the left ventricular function in patients with chronic heart failure." International Heart Journal 61.1 (2020): 1-6.

[10] Li, Jin, et al. "Application of gastroscopy based on nano carbon in the remedy of chronic pulmonary heart disease caused by helicobacter pylori." Journal of Nanoscience and Nanotechnology 21.2 (2021): 1127-1134.